BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 5.7% – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price traded down 5.7% during trading on Thursday . The company traded as low as $9.96 and last traded at $9.9850. 1,501,871 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 4,961,299 shares. The stock had previously closed at $10.59.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald upped their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Royal Bank Of Canada decreased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

The stock has a market cap of $2.49 billion, a PE ratio of -6.49 and a beta of 0.55. The stock has a fifty day moving average price of $9.50 and a 200 day moving average price of $8.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals’s revenue was up 33.6% on a year-over-year basis. During the same period last year, the company earned $0.15 earnings per share. As a group, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at about $238,930,000. RA Capital Management L.P. bought a new stake in BioCryst Pharmaceuticals in the fourth quarter worth about $123,452,000. Jupiter Topco LLC purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $95,268,000. Deerfield Management Company L.P. boosted its position in shares of BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after buying an additional 7,477,000 shares during the period. Finally, Janus Henderson Group PLC grew its stake in shares of BioCryst Pharmaceuticals by 7,807.2% during the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock valued at $57,791,000 after buying an additional 7,310,745 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.